The scale of infections has led to predictions of very high sales for the first RSV vaccines to reach the market, with analysts at SVB Leerink predicting the market could reach upwards of $10 ...

SVB Leerink’s Geoffrey Porges notes that large biopharma deals “arise from a position of distress, not strength”, and on that front that Gilead is “far from distressed.” The biopharma ...

Wednesday after the company’s fourth-quarter print. Stryker reported quarterly earnings of $4.01 per share, which beat the ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

Leerink analyst Joseph Schwartz notes Outperform-rated Sarepta (SRPT) disclosed two-year Part 1 and one-year Part 2 data from the EMBARK study with Elevidys. The firm views these topline results ...

Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.64) per share.

Leerink Partnrs also issued estimates for BridgeBio Pharma’s FY2025 earnings at ($2.77) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at $1.61 EPS, FY2028 earnings at $4.55 EPS and FY2029 ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street's Radar. In this article, we are going to take a look at where Certara Inc. (NASDAQ:CERT) stands against the other ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street's Radar. In this article, we are going to take a look at where Certara Inc. (NASDAQ:CERT) stands against the other medical AI ...